The original family of antiviral compounds—azoloazines (structural analogues of purine bases)—has been developed in the I. Postovsky Institute of Organic Synthesis of the Ural Branch of the Russian Academy of Sciences in collaboration with the Ural State Technical University and the Scientific Research Institute of Influenza, Russian Academy of Medical Science. According to biological tests, these compounds protect animals (60–90% effectiveness) against infections caused by viruses of influenza, tick-borne encephalitis, respiratory infections and a number of other socially-significant and very dangerous viral infections. The compounds are protected by the patents of the Russian Federation.

«Triazavirine», a representative of the new family of antiviral compounds, exhibits a high efficiency in suppression of reproduction of dangerous human influenza viruses, including H5N1 (“bird flu”) and H1N1 (“swine flu”). Pharmacological characteristics of Triazavirine are are superior to those of «Tamiflu» (Hoffmann La Roche), which has been the only drug accepted for treatment of bird flu, and to such famous in Russia antiviral drugs as «Arbidol» and «Remantadin». Triazavirine is efficient at all stages of the infectious process.